Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
about
Nonhuman primate models for HIV/AIDS vaccine developmentPoxvirus vectors as HIV/AIDS vaccines in humansVaccine applications of flow cytometryProfiling immunity to HIV vaccines with systems biologyProspective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic reviewSafety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adultsHumanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virusNovel directions in HIV-1 vaccines revealed from clinical trialsStrikingly poor CD8+ T-cell immunogenicity of vaccinia virus strain MVA in BALB/c mice.Nonreplicating vectors in HIV vaccines.Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesThe influence of delivery vectors on HIV vaccine efficacySystems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine.Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensDNA/MVA Vaccines for HIV/AIDSRegression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysGlycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trialModified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathwayPriming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vectorMultiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.HIV DNA Vaccine: Stepwise Improvements Make a Difference.Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adultsSequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 InfectionFirst-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesSafety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
P2860
Q26861148-8C84137F-25DB-4CC7-9214-197541AC4A07Q26995078-0FE25C39-DF78-40E3-BEE7-118DFDA33E5CQ27004341-2EEFA598-C99D-49E6-8925-A017671E8474Q27010629-23F1EAAD-6DBF-4386-A93E-D3E922180D44Q28485174-2DA59A70-9188-4612-BED3-8FE436F923B3Q28740321-B492A12F-31F6-4322-B78E-B83E334A2097Q30234773-71D6E2CD-202C-489D-8C37-04EA59575F56Q31037728-BB13350A-4A1B-465A-ADFF-C14CCA70B422Q33645528-43834752-EA04-4FF6-98A4-E7177492BF7CQ33680521-EE02CC54-B658-404A-B9D5-B02BF5A105CEQ33693891-425A7FED-FED6-4D3B-BAA2-E1DE60BADA48Q33813145-E8DA42F9-3B89-443A-A1BA-087FE3588236Q34077543-EB3DACE3-0D53-4959-A0AA-14A7A9CCE422Q34247289-61D1C814-7C52-44BA-8B83-12FD6F03B294Q34309004-E6E00F9F-4E0E-4F29-A667-B86612F461AFQ34309830-6AA003C8-5DAC-4467-801A-A2167DE34C2CQ34465228-6B2D78F3-CC48-4837-B56F-0F359D2649C1Q34492802-D6760B90-E297-414B-B268-A53C5543F703Q34729962-89DD0E7C-B28D-4017-8E4C-3EE47A70B32BQ34796206-1CF0C592-B3BE-40EC-BF73-667463832F63Q34988279-33A98E1B-AF49-46C1-9062-35B700006CC9Q35140001-6128371C-CE01-4275-920E-A515A286F3F2Q35151746-23A1B8D9-610C-449D-96DD-B79FCEC292DCQ35431516-DB7F48E7-CB92-463A-9792-53C805866EDBQ35571248-7D90A1F6-BBEB-4E5C-9E51-5ACC2D03C0CCQ35599411-4BB202DA-9E7D-40E3-B337-286CF1E000BEQ35611969-AA4D8B96-4266-4869-B3E9-B61E09FC6C98Q35677513-CC32F5BC-7799-4E7D-8DA7-4D48926BF152Q35754196-E913C504-07F7-4ED5-A75F-68728DE0C229Q35826742-EDF4636D-D8BD-4336-9A07-889641B8504FQ35883032-B5BC0124-CC21-4F8F-95F7-CBCD97B99297Q35940696-16BD1C34-7929-41A2-B6EA-FC5AA1FD6A21Q36119504-6CB5C2F8-4B30-4EEE-909C-EE7748489A6EQ36391900-E552315F-CFFA-4E80-838A-D61C694DBF2DQ36397581-00F3F3CE-451C-4C4B-B9BC-71396A4FEB6EQ36462210-94A04703-026B-4BC8-AA5E-398E463A539DQ36495581-5FF58C99-98D7-4C47-AD34-ED350DD411B7Q36593175-9E181D1D-17D4-4514-BC85-C491498DEBFCQ36668517-138A61FB-B682-4B83-8A1B-953AEB1A802EQ36697992-2570EF12-E430-4A8F-96BD-9F7296984FAD
P2860
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@ast
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@en
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@nl
type
label
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@ast
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@en
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@nl
prefLabel
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@ast
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@en
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@nl
P2093
P2860
P50
P356
P1476
Phase 1 safety and immunogenic ...... ng HIV-1 virus-like particles.
@en
P2093
Alicia Sato
Christine M Hay
Georgia D Tomaras
Harriet L Robinson
John Hural
Linda S Wyatt
Marnie L Elizaga
Massimo Cardinali
P2860
P304
P356
10.1093/INFDIS/JIQ105
P407
P577
2011-01-31T00:00:00Z